Compare the full GLP-1 program bill, not the first number shown

Why a starting price is only one line of the bill

A list that sorts online GLP-1 programs by the first monthly figure is easy to make and easy to get wrong. The reviewed pages show starting amounts from $99 to $199, yet some figures carry yearly commitments, some vary by product or dose, and some may sit beside separate care or membership charges. Total cost has to be built from line items over one defined period.

A starting price may exclude or vary with membership, clinician care, medication, dose, labs, supplies, shipping, insurance cost-sharing, or a minimum term. Found's reviewed source warns that medication and membership or clinical-care pricing may be separate. Trimi and Gala tie their lowest displayed amounts to annual or yearly plans. Shed says medication and dose can change price. Oak's page and metadata exposed different starting figures. Each qualifier can materially change what a consumer pays even when the headline is accurate in its narrow context.

The safer approach is to compare a defined basket over a defined period. Pick the exact product category and service scope being considered, then calculate the first-month amount, amount due today, and full minimum-term obligation. Keep branded FDA-approved and compounded products in separate categories; do not call them equivalent. If two programs do not disclose comparable components, the correct result may be "not enough evidence to name the lowest total," which is more useful than a false bargain.

Build the checklist before ranking providers

Create rows for intake, membership, clinician visits or messaging, medication, labs, supplies, shipping, taxes or other charges if applicable, and cancellation or renewal obligations. Add columns for amount due today, recurring amount, billing cadence, minimum term, price-change conditions, insurance involvement, and source date. For every zero, require an explicit first-party statement that the component is included or free. An unstated charge is not zero; label it "not stated" and request a written answer.

Calculate at least two totals. The first-month cash requirement shows immediate affordability. The full minimum-term total shows commitment exposure. A $99 monthly figure on an annual plan can represent a different obligation from a $199 month-to-month figure even before other services are added. Conversely, a higher starting figure may include components billed separately elsewhere. Without exact current terms, this guide does not assume either structure is better; it shows why both totals belong on the page.

Add an uncertainty field beside each amount. Mark a value confirmed when it appears in the current written quote, variable when the provider says it depends on medication, dose, eligibility, insurance, or availability, and unstated when no source answers it. This prevents precise arithmetic from creating false certainty. A total with three unknown components is not directly comparable with a complete all-in quote, even if the visible subtotal is lower.

What the $99 offers include and leave unresolved

Found advertised compounded GLP-1 options from $99 per month, but the reviewed source says other medication and membership costs vary and that medication and membership or clinical-care prices may be separate. It also offers a free insurance check, so the final consumer amount can depend on plan-specific coverage as well as separate program charges. The total-cost checklist should never use $99 as Found's all-in universal total. It should request the precise medication, care, membership, shipping, and insurance-responsibility amounts for the reader's quote.

How yourEra and Trimi qualify their starting prices

yourEra advertised compounded semaglutide from $99 and compounded tirzepatide from $169 per month, described free shipping, and used a self-pay model. That gives the checklist clearer product-specific starting figures and a sourced shipping zero, but it still does not establish every included service, future price, or wait time. HSA or FSA use may depend on the plan administrator, so potential account use should be listed separately from price and never treated as guaranteed coverage.

Trimi advertised compounded semaglutide from $99 and compounded tirzepatide from $125 per month on an annual plan, with free overnight shipping. The published product-specific amounts and shipping statement are useful, while the annual condition requires a minimum-term calculation. The checklist should capture whether payment is prepaid or installment-based, the amount due initially, renewal and cancellation rules, and included care. A low normalized monthly amount can coexist with higher commitment risk.

How Oak, Gala, and Shed change the comparison

Oak Longevity advertised its program from $119 per month, but current page details listed other price points, so the reviewed sources require checkout verification. That conflict is itself a total-cost risk signal. The checklist should not choose the lowest exposed figure. It should preserve the page and checkout evidence, identify the exact product and plan, confirm the amount due and renewal, and mark service area as unstated because it was not supplied on the reviewed page. Free tracked delivery can be recorded as a sourced shipping feature.

Gala advertised compounded GLP-1/GIP from $179 per month on a yearly subscription plan. It stated self-pay pricing and a nationwide pharmacy network, but the shipping fee was not stated in the reviewed evidence. The annual commitment and missing shipping-fee field belong in the calculation. Ask whether the quote is prepaid, how it renews, which clinician or program services are included, and what cancellation means for remaining charges. Do not let the monthly normalization obscure the contractual horizon.

Shed advertised its GLP-1 injection program from $199 per month, said medication and dose can change price, and described insurance or cash-pay options plus free shipping. The checklist can record free shipping, but it must request the exact quote after the product and payment pathway are known. Insurance assistance does not make the cost zero and does not guarantee coverage. The service area also requires direct verification because it was not fully enumerated on the reviewed page.

Keep product status separate from payment method

A total-cost table must label branded FDA-approved and compounded products separately. The FDA states that compounded drugs are not FDA-approved and do not receive FDA premarket review for safety, effectiveness, and quality. That regulatory fact does not authorize a blanket outcome comparison, and it does not mean products should be called interchangeable. It means a price table must not hide category differences behind the shared phrase "GLP-1." This guide makes no safety, effectiveness, or treatment recommendation.

Insurance belongs in its own columns: support offered, service checked, insurer response, prior-authorization status if applicable, consumer responsibility, separate membership, and expiration or recheck date. Found's free insurance check and Shed's insurance-or-cash-pay language are support features. They are not guaranteed coverage. Self-pay programs such as yourEra, Trimi, and Gala can be compared without predicting insurer behavior, but their HSA or FSA language, when present, still requires administrator confirmation.

The lowest cost may also change over time because coverage, plan terms, product availability, and provider prices are mutable. Save the source date and quote expiration. Recalculate before renewal rather than assuming the enrollment total continues indefinitely.

When a cheapest-program statement is supportable

Name a lowest-total option only when quotes cover the same product category, service scope, location, payment path, and time horizon, with every material line item confirmed. If one quote excludes care, another requires an annual term, and a third depends on insurance, there is no defensible single winner. Report the confirmed subtotals and uncertainty instead. This prevents a commercially convenient starting price from being promoted as a universal bargain.

Real pros and cons follow from this method. A published price, explicit plan qualifier, included shipping statement, or clear insurance-check process is a pro because it reduces ambiguity. A long commitment, variable medication or dose pricing, conflicting page details, separate undisclosed care fees, unstated shipping, or unenumerated service area is a con because it increases uncertainty or obligation.

Verify the quote and test the budget

Before paying, obtain the official quote, terms, cancellation rules, and itemized scope in writing. Keep clinical questions, eligibility, product choice, risks, and expected effects, separate and discuss them with a qualified healthcare professional. The commercial conclusion is modest but actionable: compare complete obligations over the same period, refuse to convert unknowns into zeroes, and decline to call any option cheapest until the evidence supports the claim.

Stress-test the budget with at least one plausible commercial change. Recalculate if a promotional starting rate ends, an insurance estimate becomes a denial, a product or dose changes the quoted amount, or a consumer wants to leave before the minimum term ends. This is not a prediction that any event will happen. It is a way to expose which term creates the largest financial risk. A program with a higher confirmed base total may still be easier to budget than a lower subtotal with several unresolved variables.

Document the comparison's boundaries in the final verdict. State the checked date, product categories, location, payment pathway, period, and excluded unknowns. If the result applies only to compounded self-pay offers under annual plans, say so. If insurance responses are estimates, say so. Narrow wording makes the result more reusable and easier to update. It also avoids implying that one commercial total establishes regulatory equivalence, clinical quality, eligibility, or an expected outcome. A precise non-winner is better than a broad unsupported winner.